Holen Sie sich die Stockscreener-App
0.8526
12.15%
-0.1179
Vorhandelsmarkt:
.75
-0.1026
-12.03%
Schlusskurs vom Vortag:
$0.9705
Offen:
$0.9916
24-Stunden-Volumen:
869.79K
Relative Volume:
0.21
Marktkapitalisierung:
$3.60M
Einnahmen:
$112.00K
Nettoeinkommen (Verlust:
$-15.75M
KGV:
-0.0571
EPS:
-14.9263
Netto-Cashflow:
$-13.33M
1W Leistung:
-16.41%
1M Leistung:
-16.41%
6M Leistung:
-70.37%
1J Leistung:
+519.79%
1-Tages-Spanne:
$0.8401
$0.9916
1-Wochen-Bereich:
$0.8401
$1.05
52-Wochen-Spanne:
$0.0632
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.8526 | 3.60M | 112.00K | -15.75M | -13.33M | -14.93 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider Monkey
What's going on with AIM ImmunoTech stock Friday? - MSN
If You Invested $1,000 in Aim Immunotech (AIM) - Stock Titan
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
Why did AIM stock more than double in pre-market today? - MSN
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results - Sahm
AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress - International Business Times
Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Micron And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAIM ImmunoTech (AMEX:AIM), Almonty Indus (NASDAQ:ALM) - Benzinga
AIM ImmunoTech Inc. (AIM) Latest Stock News & Headlines - Yahoo Finance
AIM ImmunoTech Gains Japanese Patent Approval for Cancer Treatme - GuruFocus
Why Five Below Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
AIM ImmunoTech (AIM) Stock Soars Nearly 100% on Japanese Cancer Treatment Patent Approval - MEXC
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Stock Jumps 97% After Japan Patent Approval for Cancer Treatment - MEXC
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer - GlobeNewswire
AIM ImmunoTech Expands Cancer Drug Trials with Key Collaboration - StocksToTrade
AIM ImmunoTech Engages Thermo Fisher’s PPD for Phase 3 Cancer Trial - timothysykes.com
Patent Approval Drives Stock Price Surge: AIM ImmunoTech Inc. (AIM) shares soared 88% in pre-market trading today, reaching $1.34 - Bitget
Why Is AIM ImmunoTech Stock (AIM) Up Today? - TipRanks
Dow Falls Over 150 POints; US Producer Prices Increase In February - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - Bitget
Why Did AIM Stock More Than Double In Pre-Market Today? - Asianet Newsable
Patent Implementation and Core Therapy: AIM ImmunoTech Inc. announces that its innovative cancer therapy patent combining Ampligen with immune checkpoint inhibitors has received final approval in Japan - Bitget
AIM ImmunoTech announces final approval of novel cancer therapy patent in Japan combining Ampligen with checkpoint inhibitors - marketscreener.com
Aim Immunotech Announces Final Approval Of Novel Cancer Therapy Patent In Japan Combining Ampligen With Checkpoint Inhibitors - TradingView
AIM ImmunoTech (AIM) CEO converts Series G preferred into 25,000 common shares - Stock Titan
AIM ImmunoTech (AIM) director converts Series G preferred into 25,000 shares - Stock Titan
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech (AIM) director gets Series G preferred and 50,000 warrants - Stock Titan
AIM ImmunoTech Inc. Signs Dealer-Manager Agreement with Maxim Group LLC for Rights Offering – SEC Form 8-K Filing March 2026 - Minichart
AIM ImmunoTech completes rights offering, creates new preferred stock series By Investing.com - Investing.com Australia
Cancer-drug developer AIM ImmunoTech draws $1.8M in $1,000 rights sale - Stock Titan
AIM ImmunoTech Announces Closing of its Rights Offering - Caledonian Record
AIM ImmunoTech Completes Series G Preferred Rights Offering - TipRanks
AIM ImmunoTech completes rights offering, creates new preferred stock series - Investing.com
AIM ImmunoTech Appoints Equiniti as Warrant Agent for $1.8 Million Rights Offering - TradingView
AIM ImmunoTech (NYSE: AIM) raises $1.8M, issues Series G preferred and warrants - Stock Titan
Advance Information Marketing Bhd. (AIM) - Minichart
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Bitget
AIM ImmunoTech (AIM) Projects $1.8M from Rights Offering - GuruFocus
Aim Immunotech Announces Expiration And Preliminary Results Of Its Rights Offering For Aggregate Gross Proceeds Of $1.8 Million - TradingView
AIM ImmunoTech raises $1.8M with $1,000 preferred stock and warrant bundles - Stock Titan
AIM ImmunoTech Signs Agreement for Planning of a Proposed - GlobeNewswire
AIM Collaborates with Thermo Fisher for Phase 3 Trial of Amplige - GuruFocus
AIM ImmunoTech Inc. has signed an agreement to plan a proposed Phase III clinical trial of its core candidate drug Ampligen for the treatment of advanced pancreatic cancer. - Bitget
Experimental pancreatic cancer drug Ampligen moves toward Phase 3 test - Stock Titan
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):